Key Takeaways
- Steady quarter, margin-led beat: Revenue grew +9.8% YoY to ₹552 crores, but the real story was EBITDA margin expanding 102 bps YoY to 12.4%, driven by mix and cost control.
- Paracetamol is the swing asset: The new 10,800 MTPA plant is now exporting to Europe, and utilization is set to jump from 34% to 60% by Q3, pulling both revenue and margins upward.
- Portfolio rebalancing is underway: Management is shifting non-Ibuprofen APIs like Clopidogrel and Pantoprazole into regulated markets for better realizations, targeting a 50-50 split between Ibuprofen and non-Ibuprofen revenue.
- Export ambition is explicit but back-end loaded: Exports sit at 25% of revenue today; the target is 40% in two years, contingent on customer audits and regulatory approvals that are still in process.
- What to watch next quarter: Whether the Paracetamol utilization ramp to 60% stays on track, any progress on regulated-market customer audits for the non-Ibuprofen portfolio, and if chemical segment pricing finds a floor.
Paracetamol: The Near-Term Growth Engine
- Demand above pre-COVID, pricing at trough: Volume demand is growing at ~3%-4% annually and sits above pre-pandemic levels, but realizations are at very low levels, with a blended average of USD 3 to USD 3.5 per kg across domestic and export. Export prices carry a 10%-20% premium over domestic.
- New plant unlocks scale and margin: The 10,800 MTPA facility is fully automated and backward-integrated with para-aminophenol and Acetic Anhydride, which means every unit of incremental volume drops through at a higher margin than the legacy plant.
- Utilization ramp is the lever: Capacity utilization was just 34% in Q1, with a clear line of sight to 60% by Q3 FY26 and optimum levels next financial year. That incremental volume, combined with the plant's cost structure, is the single largest contributor to the margin expansion story.
- Old plant repurposed for Metformin: Once production fully shifts to the new plant, the legacy 4,000 MTPA Paracetamol line will be converted to Metformin, adding to the existing 7,600 MTPA capacity and deepening the non-Ibuprofen portfolio.
Mahajan: "As regarding Paracetamol, the prices are no doubt at a very low level, but the demand is there, not at that level which was during the COVID period. But it is already above the pre-COVID arena area."
Portfolio Diversification & the Non-Ibuprofen Push
- The 50-50 ambition: Management wants to reduce dependence on Ibuprofen by growing the non-Ibuprofen API portfolio to an equal revenue share, targeting peak revenue of ₹900-1,000 crores from that segment in 2-3 years, up from ~₹500 crores currently.
- Regulated-market pivot is the margin play: Products like Clopidogrel, Pantoprazole Sodium, and Fenofibrate are being shifted from semi-regulated to regulated markets (Europe, LATAM, US) where realizations are structurally higher. Utilization on Clopidogrel and Pantoprazole is already at 70%-80%, and customer audits are underway.
- Minoxidil adds a niche growth vector: A dedicated 120-tonne facility carved from the old Gabapentin plant is expected by Q3 FY26, targeting peak revenue of ₹50-60 crores plus intermediate sales. The product was chosen because it already had validation, stability, and shelf-life data, shortening the time to market.
- Metformin runs hot: Existing capacity utilization is above 90%, and the repurposed Paracetamol plant will add 4,000 MTPA once the transition completes, signaling strong underlying demand for the molecule.
- Patent portfolio building slowly: Three patents secured (Valsartan, Sitagliptin, Losartan), with the third still in filing stage, providing a long-dated optionality on complex generics.
Mahajan: "We are setting up a capacity of around 120 tonnes of Minoxidil. And at the peak level, we are expecting a revenue of 50 to 60 from Minoxidil in addition to the intermediate sales."
Export Strategy & Regulatory Pathway
- The 40% target is a two-year journey: Exports currently contribute 25% of total company revenue. Management aims to lift that to 40% within two years, driven by regulated-market entries across Europe, LATAM, and China.
- Europe is the near-term catalyst: API demand is slowly increasing as customer approvals progress, and the company holds a CEP for most products. The REACH registration for Acetic Anhydride opens an additional European channel, with surplus quantities (after captive Paracetamol consumption) sold into higher-realization markets.
- US pathway is less certain: DMFs for Fenofibrate and Levetiracetam received observations in the last week, though both products were approved for the US market two months ago. Management noted the USFDA can approve without physical inspection (citing Metformin as precedent), but no inspection timeline was given, and the tariff environment remains an unknown.
- EU GMP audit planned for November: A key gating item for deeper European penetration, with the outcome directly affecting the pace of regulated-market revenue conversion.
Khanna: "Actually, the current situation of export and domestic is 75% approximately and 25% export. And we are targeting to increase the export to 40% of total revenue in the coming two years."
Margins: The 14%-15% Path
- The quarter's margin walk: EBITDA margin reached 12.4%, up 102 bps YoY, driven by better product mix, cost optimization, and improved capacity utilization. Cash PAT grew over 16% YoY to ₹55 crores, reflecting strong underlying cash generation on a zero-leverage balance sheet.
- Chemical segment remains a drag: Steady demand but subdued pricing across key products, with soft market sentiment from cautious downstream procurement. Management expects chemical segment EBITDA margins of just 5%-6% for FY26, which caps consolidated margin upside until pricing recovers.
- The 14%-15% guidance is firm but not aggressive: Management reiterated the target and said strategies are being executed, but explicitly clarified they are not guiding to 15% plus. The tone was confident but timeline-agnostic: "it is a matter of sometime only."
- Raw material expense optics: The ~₹50 crore increase in raw material costs was partly inflated by a ₹12 crore rise in finished goods inventory, meaning the underlying cost pressure was less severe than the headline number suggests.
Singh: "See, this is like we are having very clear cut and focus, vision and we are just going all those, our strategies are just getting through. So, we are pretty sure that we will be having it. It is a matter of sometime only."
Capex, Capacity & the Next Growth Phase
- New land parcel acquired: A 100-acre site near the Chandigarh-Bhatinda highway has been secured for future chemical and API expansion. Environmental clearance is in process: the public hearing is complete and a ministry meeting was held on July 29.
- Annual capex run-rate: ₹150-200 crores planned for FY26, with growth capex details to be shared quarterly as approvals mature. The balance sheet carries no leverage, providing headroom to fund this without strain.
- Unit 9B for Minoxidil: A dedicated facility carved from existing Unit 9, expected by Q3 FY26, represents the first tangible output of the repurposing strategy for older assets.
- Acetic Anhydride captive consumption rising: As Paracetamol utilization ramps, more Acetic Anhydride will be consumed internally, with only surplus volumes sold into the EU market under the new REACH registration. This improves integrated margins on Paracetamol while maintaining an export option for the intermediate.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Paracetamol capacity utilization | Increase from 34% to 60% | Q3 FY26 |
| Paracetamol capacity utilization | Reach optimum level | Next financial year (FY27) |
| Consolidated EBITDA margin | Achieve 14% to 15% | FY26 (full year) |
| Chemical segment EBITDA margin | 5% to 6% | FY26 |
| Revenue growth | 10% growth over last year | FY26 |
| Top-line | ₹600 crores, or very close | FY26 |
| Ibuprofen + non-Ibuprofen revenue | ₹2,000 crores | Next two years |
| Non-Ibuprofen peak revenue | ₹900 to ₹1,000 crores | 2-3 years |
| Export share of total revenue | 40% (from 25% currently) | Coming two years |
| Minoxidil facility completion | Unit 9B operational | Q3 FY26 |
| Minoxidil peak revenue | ₹50 to ₹60 crores plus intermediate sales | At peak utilization (undated) |
| Annual capex | ₹150 to ₹200 crores | FY26 |
| EU GMP audit | Planned | November |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Revenue from operations | ₹552 cr, 9.8% YoY growth from ₹502 cr in Q1 FY25 |
| EBITDA | ₹69.5 cr, 19.5% YoY growth from ₹58.2 cr in Q1 FY25 |
| EBITDA margin | 12.4%, improvement of 102 bps YoY |
| Profit after tax | ₹34 cr, 14.4% YoY increase from ₹29.7 cr in Q1 FY25 |
| Cash PAT | ₹55 cr, over 16% YoY growth from ₹47 cr in Q1 FY25 |
| Revenue growth guidance for FY26 | 10% growth from FY25 |
| Blended EBITDA margin guidance | 14% to 15% |
| Chemical segment EBITDA margin guidance for FY26 | 5% to 6% |
| Ibuprofen and non-Ibuprofen segment revenue target | ₹2,000 cr in the next two years |
| Non-Ibuprofen API revenue share | 34% of total API revenue (per an analyst's math) |
| Non-Ibuprofen API peak revenue target | ₹900 cr to ₹1,000 cr in 2–3 years, from current ~₹500 cr |
| Export revenue share | 25% of total revenue, targeting 40% in two years |
| Paracetamol plant capacity utilization | 34% in Q1, expected to reach 60% by Q3 FY26 |
| Metformin capacity utilization | more than 90% |
| CAPEX plan for FY26 | ₹150 cr to ₹200 cr |